Antimicrobial resistance and the management of anaerobic infections

References

• Jousimies-Somer H, Summanen P, Citron D, Baron EJ, Wexler HM, Finegold SM. Wadsworth Anaerobic Bacteriology Manual. Hoffman S (Ed.). Star Publishing Company, CA, USA (2002).
   Google Scholar
• Fille M, Mango M, Lechner M, Schaumann R. Bacteroides fragilis group: trends in resistance. Curr. Microbiol.52(2), 153–157 (2006).
   PubMed Web of Science ®Google Scholar
• Katsandri A, Papaparaskevas J, Pantazatou A et al. Two cases of infections due to multidrug-resistant Bacteroides fragilis group strains. J. Clin. Microbiol.44(9), 3465–3467 (2006).
   PubMed Web of Science ®Google Scholar
• Wybo I, Pierard D, Verschraegen I et al. Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J. Antimicrob. Chemother.59(1), 132–139 (2007).
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob. Agents Chemother.51(5), 1649–1655 (2007).
   PubMed Web of Science ®Google Scholar
• Papaparaskevas J, Pantazatou A, Katsandri A et al. Multicentre survey of the in vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece. Clin. Microbiol. Infect.11(10), 820–824 (2005).
   PubMed Web of Science ®Google Scholar
• Liebetrau A, Rodloff AC, Behra-Miellet J, Dubreuil L. In vitro activities of a new des-fluoro(6)quinolone, garenoxacin, against clinical anaerobic bacteria. Antimicrob. Agents Chemother.47(11), 3667–3671 (2003).
   PubMed Web of Science ®Google Scholar
• Betriu C, Rodriguez-Avial I, Gomez M, Culebras E, Picazo JJ. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997–2002). Diagn. Microbiol. Infect. Dis.53(3), 221–223 (2005).
   PubMedGoogle Scholar
• Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin. Infect. Dis.39(1), 92–97 (2004).
   PubMed Web of Science ®Google Scholar
• Roberts SA, Shore KP, Paviour SD, Holland D, Morris AJ. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999–2003. J. Antimicrob Chemother.57(5), 992–998 (2006).
   PubMed Web of Science ®Google Scholar
• Behra-Miellet J, Dubreuil L, Bryskier A. In vitro evaluation of faropenem activity against anaerobic bacteria. J. Chemother.17(1), 36–45 (2005).
   PubMed Web of Science ®Google Scholar
• Boyanova L, Kolarov R, Gergova G et al. Anaerobic bacteria in 118 patients with deep-space head and neck infections from the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria. J. Med. Microbiol.55(Pt 9), 1285–1289 (2006).
   PubMed Web of Science ®Google Scholar
• Pankuch GA, Appelbaum PC. Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species. Antimicrob. Agents Chemother.50(3), 1112–1117 (2006).
   PubMedGoogle Scholar
• Koeth LM, Good CE, Appelbaum PC et al. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J. Antimicrob. Chemother.53(6), 1039–1044 (2004).
   PubMed Web of Science ®Google Scholar
• Fraise AP. Tigecycline: the answer to β-lactam and fluoroquinolone resistance? J. Infect.53(5), 293–300 (2006).
   PubMed Web of Science ®Google Scholar
• Sóki J, Edwards R, Hedberg M, Fang H, Nagy E, Nord CE. Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey. Int. J. Antimicrob. Agents28(6), 497–502 (2006).
   PubMed Web of Science ®Google Scholar
• Wexler HM, Engel AE, Glass D, Li C. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob. Agents Chemother.49(10), 4413–4417 (2005).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Wiebe R, Dilay L et al. Comparative review of the carbapenems. Drugs67(7), 1027–1052 (2007).
   PubMed Web of Science ®Google Scholar
• Fulco P, Wenzel RP. Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Rev. Anti Infect. Ther.4(6), 939–945 (2006).
   PubMedGoogle Scholar
• Goldstein EJC, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez HT. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections. Antimicrob. Agents Chemother.50(8), 2875–2879 (2006).
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM, Merriam CV, Warren Y, Tyrrell KL, Fernandez H. In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis. Antimicrob. Agents Chemother.47(6), 1963–1967 (2003).
   PubMedGoogle Scholar
• Arundel C, Lewis JH. Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol.23(3), 244–254 (2007).
   PubMedGoogle Scholar
• Brook I. Management of anaerobic infections. Expert Rev. Anti Infect. Ther. 2004, 2(1), 153–158 (2004).
   PubMedGoogle Scholar
• Goldstein EJC, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob. Agents Chemother.50(10), 3507–3513 (2006).
   PubMed Web of Science ®Google Scholar
• Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy26(8), 1099–1110 (2006).
   PubMed Web of Science ®Google Scholar
• Katsandri A, Avlamis A, Pantazatou A et al.In vitro activities of tigecycline against recently isolated Gram-negative anaerobic bacteria in Greece, including metronidazole-resistant strains. Diagn. Microbiol. Infect. Dis.55(3), 231–236 (2006).
   PubMedGoogle Scholar
• Theron MM, Janse Van Rensburg MN, Chalkley LJ. Nitroimidazole resistance genes (nimB) in anaerobic Gram-positive cocci (previously Peptostreptococcus spp.). J. Antimicrob. Chemother.54(1), 240–242 (2004).
   PubMed Web of Science ®Google Scholar
• Mory F, Carlier JP, Alauzet C, Thouvenin M, Schuhmacher H, Lozniewski A. Bacteremia caused by a metronidazole-resistant Prevotella sp. strain. J. Clin. Microbiol.43(10), 5380–5383 (2005).
   PubMedGoogle Scholar
• Hoffman PS, Sisson G, Croxen MA et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni.Antimicrob. Agents Chemother.51(3), 868–876 (2007).
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J. Antimicrob. Chemother.59(4), 705–710 (2007).
   PubMed Web of Science ®Google Scholar
• Gajjar DA, Bello A, Ge Z, Christopher L, Grasela DM. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob. Agents Chemother.47(7), 2256–2263 (2003).
   PubMed Web of Science ®Google Scholar
• Stein GE, Goldstein EJ. Fluoroquinolones and anaerobes. Clin. Infect. Dis.42(11), 1598–1607 (2006).
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez H. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother.50(1), 148–155 (2006).
   PubMed Web of Science ®Google Scholar
• Ouhara K, Komatsuzawa H, Yamada S et al. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, (β)-defensins and LL37, produced by human epithelial cells. J. Antimicrob. Chemother.55(6), 888–896 (2005).
   PubMed Web of Science ®Google Scholar
• Odou MF, Muller C, Calvet L, Dubreuil L. In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections. J. Antimicrob. Chemother.59(4), 646–651 (2007).
   PubMed Web of Science ®Google Scholar
• Brook I. Microbiology of polymicrobial abscesses and implications for therapy. J. Antimicrob. Chemother.50(6), 805–810 (2002).
   PubMed Web of Science ®Google Scholar
• Marina M, Ivanova K, Ilieva T. Susceptibility of anaerobic bacteria to antimicrobial agents in Bulgaria. Proceedings of the 1st Conference of the Bulgarian Association of Medical Microbiology: Rational Antibiotic Policy. Sofia, Bulgaria, 4–6 June 2005.
   Google Scholar
• Teng LJ, Hsueh PR, Tsai JC, Liaw SJ, Ho SW, Luh KT. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan. Antimicrob. Agents Chemother.46(9), 2908–2913 (2002).
   PubMed Web of Science ®Google Scholar
• Hecht DW. Routine anaerobic blood cultures: back where we started? Clin. Infect. Dis.44(7), 901–903 (2007).
   PubMedGoogle Scholar
• Lassmann B, Gusrafson DR, Wood CM, Rosenblatt JE. Reemergence of anaerobic bacteremia. Clin. Infect. Dis.44(7), 895–900 (2007).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Berendt AR, Deery HG et al. Diagnosis and treatment of diabetic foot infections. Plast. Reconstr. Surg.117(7 Suppl.), 212S–238S (2006).
   PubMed Web of Science ®Google Scholar
• Senneville E, Savage C, Nallet I et al. Improved aero-anaerobe recovery from infected prosthetic joint samples taken from 72 patients and collected intraoperatively in Rosenow’s broth. Acta Orthop.77(1), 120–124 (2006).
   PubMed Web of Science ®Google Scholar
• Brook I. Ocular infections due to anaerobic bacteria. Int. Ophthalmol.24(5), 269–277 (2001).
   PubMedGoogle Scholar
• Chaudhry IA, Shamsi FA, Al-Rashed W. Bacteriology of chronic dacryocystitis in a tertiary eye care center. Ophthal. Plast. Reconstr. Surg.21(3), 207–210 (2005).
   PubMed Web of Science ®Google Scholar
• Hartikainen J, Lehtonen OP, Saari KM. Bacteriology of lacrimal duct obstruction in adults. Br. J. Ophthalmol.81(1), 37–40 (1997).
   PubMedGoogle Scholar
• Brook I. The role of anaerobic bacteria in upper respiratory tract and other head and neck infections. Curr. Infect. Dis. Rep.9(3), 208–217 (2007).
   PubMedGoogle Scholar
• Rega AJ, Aziz SR, Ziccardi VB. Microbiology and antibiotic sensitivities of head and neck space infections of odontogenic origin. J. Oral Maxillofac. Surg.64(9), 1377–1380 (2006).
   PubMed Web of Science ®Google Scholar
• Brook I. Microbiology and management of peritonsillar, retropharyngeal, and parapharyngeal abscesses. J. Oral Maxillofac. Surg.62(12), 1545–1550 (2004).
   PubMed Web of Science ®Google Scholar
• Brook I. Microbiology of intracranial abscesses and their associated sinusitis. Arch. Otolaryngol. Head Neck Surg.131(11), 1017–1019 (2005).
   PubMedGoogle Scholar
• Boyanova L, Djambazov V, Gergova G et al. Anaerobic microbiology in 198 cases of pleural empyema. A Bulgarian study. Anaerobe10(5), 261–267 (2004).
   PubMed Web of Science ®Google Scholar
• Allewelt M, Schuler P, Bolcskei PL. Ampicillin + sulbactam vs clindamycin ± cephalosporin for the treatment of aspiration pneumonia and primary lung abscess. Clin. Microbiol. Infect.10(2), 163–170 (2004).
   PubMed Web of Science ®Google Scholar
• Stelzmueller I, Berger N, Wiesmayr S et al. Group milleri streptococci: significant pathogens in solid organ recipients. Transpl. Int.20(1), 51–56 (2007).
   PubMedGoogle Scholar
• Kioumis IP, Kuti JL, Nicolau DP. Intra-abdominal infections: considerations for the use of the carbapenems. Expert Opin. Pharmacother.8(2), 167–182 (2007).
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin. Infect. Dis.37(8), 997–1005 (2003).
   PubMed Web of Science ®Google Scholar
• Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs65(12), 1611–1620 (2005).
   PubMed Web of Science ®Google Scholar
• Solomkin J, Teppler H, Graham DR et al. Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin–tazobactam. J. Antimicrob. Chemother.53(Suppl. 2), ii51–ii57 (2004).
   PubMed Web of Science ®Google Scholar
• Lin WJ, Lo WT, Chu CC, Chu ML, Wang CC. Bacteriology and antibiotic susceptibility of community-acquired intra-abdominal infection in children. J. Microbiol. Immunol. Infect.39(3), 249–254 (2006).
   PubMedGoogle Scholar
• Brook I. Microbiology and management of polymicrobial female genital tract infections in adolescents. J. Pediatr. Adolesc. Gynecol.15(4), 217–226 (2002).
   PubMedGoogle Scholar
• Haggerty CL, Ness RB. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. Clin. Infect. Dis.44(7), 953–960 (2007).
   PubMedGoogle Scholar
• CDC. Sexually transmitted diseases treatment guidelines 2006. Morb. Mortal. Wkly Rep.55(RR–11), 1–94 (2006).
   PubMedGoogle Scholar
• Haggerty CL, Totten PA, Astete SG, Ness RB. Mycoplasma genitalium among women with nongonococcal, nonchlamydial pelvic inflammatory disease. Infect. Dis. Obstet. Gynecol.14(3), 30184 (2006).
   Google Scholar
• CDC. Update to CDC’s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. Morb. Mortal. Wkly Rep.56(14), 332–336 (2007).
   PubMedGoogle Scholar
• Goldstein EJC, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of garenoxacin (bms 284756) against 108 clinical isolates of Gardnerella vaginalis.Antimicrob. Agents Chemother.46(12), 3995–3996 (2002).
   PubMed Web of Science ®Google Scholar
• Larsson PG, Forsum U. Bacterial vaginosis – a disturbed bacterial flora and treatment enigma. APMIS113(5), 305–316 (2005).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis.41(10), 1373–1406 (2005).
   PubMed Web of Science ®Google Scholar
• Pulverer G, Schutt-Gerowitt H, Schaal KP. Human cervicofacial actinomycoses: microbiological data for 1997 cases. Clin. Infect. Dis.37(4), 490–497 (2003).
   PubMed Web of Science ®Google Scholar
• Edwards R, Harding KG. Bacteria and wound healing. Curr. Opin. Infect. Dis.17(2), 91–96 (2004).
   PubMed Web of Science ®Google Scholar
• Taplitz RA. Managing bite wounds: currently recommended antibiotics for treatment and prophylaxis. Postgrad. Med.116(2), 49–59 (2004).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet366(9498), 1695–1703 (2005).
   PubMed Web of Science ®Google Scholar
• Surowiec D, Kuyumjian AG, Wynd MA, Cicogna CE. Past, present, and future therapies for Clostridium difficile-associated disease. Ann. Pharmacother.40(12), 2155–2163 (2006).
   PubMed Web of Science ®Google Scholar
• Thorpe CM, Gorbach SL. Update on Clostridium difficile.Curr. Treat. Options Gastroenterol.9(3), 265–271 (2006).
   PubMedGoogle Scholar
• Edlich RF, Hill LG, Mahler CA et al. Management and prevention of tetanus. J. Long Term Eff. Med. Implants13(3), 139–154 (2003).
   PubMedGoogle Scholar
• Sobel J. Botulism. Clin. Infect. Dis.41(8), 1167–1173 (2005).
   PubMed Web of Science ®Google Scholar
• Maestre Vera JR, Gomez-Lus Centelles ML. Antimicrobial prophylaxis in oral surgery and dental procedures. Med. Oral Patol. Oral Cir. Bucal.12(1), E44–E52 (2007).
   PubMedGoogle Scholar
• De Lalla F. Perioperative antibiotic prophylaxis: a critical review. Surg. Infect. (Larchmt)7(Suppl. 2), S37–S39 (2006).
   PubMedGoogle Scholar
• Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA (Eds). The Sanford Guide to Antimicrobial Therapy. Antimicrobial Therapy, Inc., VT, USA (2005).
   Google Scholar